Spotlight On

With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.

Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.

For several decades, therapy for acute myeloid leukemia (AML) was rather straightforward. But now that we have a deeper understanding of the pathogenesis of AML, this has led to the identification of potential therapeutic targets that give us options in addition to standard intensive chemotherapy, as Dr. Harry Erba explains.

BCL2-US-00026-MC
Version 2.0, Approved November 2020

Although survival among younger patients with acute myeloid leukemia (AML) has improved over the past decade, older patients continue to have a poor prognosis. And since age and frailty are the primary predictors of outcome among patients with AML, Dr. Harry Erba shares how the treatment of older patients with AML may be changing.

BCL2-US-00027-MC
Version 2.0, Approved November 2020

In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts.

ABBV-US-00196-MC
Version 1.0, Approved August 2020

For patients with COPD, exacerbations can have an irreversible and sustained impact on their daily life.3,4 Additionally, exacerbations are often underreported.5 That’s why Dr. MeiLan Han is here to walk us through the importance of exacerbation recognition and prevention, the health and life burdens of exacerbations, and patient-physician communication gaps.

References:

1. Halpin DMG, Decramer M, Celli BR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85-91.
2. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091-1097.
3. O’Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155(1):109-115.
4. Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54-57.
5. Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(3):316-325.

©2020 AstraZeneca. All rights reserved. US-42455 Last Updated 8/20

To help address the gap in awareness across the field regarding the development of psoriatic arthritis, Dr. Roger Kornu joins Dr. Matt Birnholz at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to discuss commonly overlooked symptoms, including plaque psoriasis, dactylitis, and enthesitis.

PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

As stated by Dr. Sanjay Chabra, "About 19 percent of the population lives with chronic back pain, but what about when it’s inflammatory—not mechanical—back pain?" Join Dr. Matt Birnholz as he sits down with Dr. Chabra at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to share strategies that can help us shorten the delay in the diagnosis of ankylosing spondylitis that often occurs within and around rheumatology practices.

PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

To help address the gap in awareness across the field regarding the development of psoriatic arthritis, Dr. Roger Kornu joins Dr. Matt Birnholz at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to discuss commonly overlooked symptoms, including plaque psoriasis, dactylitis, and enthesitis.

PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.

As stated by Dr. Sanjay Chabra, "About 19 percent of the population lives with chronic back pain, but what about when it’s inflammatory—not mechanical—back pain?" Join Dr. Matt Birnholz as he sits down with Dr. Chabra at the 2019 American College of Rheumatology annual meeting in Atlanta, Georgia, to share strategies that can help us shorten the delay in the diagnosis of ankylosing spondylitis that often occurs within and around rheumatology practices.

PP-IX-US-3710 04/2020 ©Lilly USA, LLC 2020. All rights reserved.